secwatch.observer — SEC 8-K summary
======================================

Issuer:     Oncology Institute, Inc. (TOI)
CIK:        0001799191
Form:       8-K
Filed at:   2025-03-24T23:59:59+00:00
Accession:  0001079973-25-000446
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TOI Q4 2024 revenue up 16.9% to $100M; net loss narrows to $13.2M; 2025 guidance revenue $420-450M
--------------------------------------------------------------------------------

- Revenue $100M (+16.9% YoY); net loss $13.2M vs $18.8M; EPS -$0.14 vs -$0.21.
- Positive Q4 operating cash flow of $4.2M; SG&A down 12% YoY.
- Added six new value-based contracts in H2 2024 covering over 250k lives; dispensary revenue at record.
- 2025 guidance: revenue $420-$450M, adjusted EBITDA loss $19-$24M, improved free cash flow.
- New drug-supplier agreement expected to improve discounts and cost positioning.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1799191/000107997325000446/0001079973-25-000446-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1799191/000107997325000446/toi_8k.htm
  HTML page:      https://secwatch.observer/filing/0001079973-25-000446

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer